Niagen Bioscience, Inc. current report, 13 September 2016

SEC Filing Summary: ChromaDex Corporation (8-K)

Business Context and Reporting Period

This Form 8-K was filed by ChromaDex Corporation on September 13, 2016. The report serves as a Regulation FD disclosure regarding a corporate investor presentation released on the same date. The presentation was prepared for the Rodman & Renshaw 18th Annual Global Investment Conference held in New York, NY. The filing explicitly states that the information is "furnished" and not "filed" for liability purposes under Section 18 of the Securities Exchange Act of 1934.

Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts solely as a notice of the availability of an investor presentation (Exhibit 99.1) and does not contain the financial data itself.

Material Changes

No material changes to financial performance or operations are detailed in the text of this filing. The report does not compare current metrics to prior periods.

Guidance, Outlook, and Risks

The filing does not contain specific guidance, outlook, management commentary, or risk factors. It references an attached investor presentation (Exhibit 99.1) where such information may be discussed, but the content of that presentation is not included in the provided text.

Key Facts for Investor Verification

  • Verify the content of Exhibit 99.1 (Investor Presentation) for actual financial data and strategic outlook.
  • Confirm the date of the Rodman & Renshaw conference presentation (September 13, 2016).
  • Note that this 8-K filing is a procedural disclosure and does not constitute a formal filing of financial statements.
  • Check subsequent filings for any updates or corrections to the information presented in the investor deck.